Managed Healthcare Executive March 5, 2024
Both Wyost and Jubbonti are interchangeable for the reference products and are approved for all of the same indications in osteoporosis and bone cancer.
The FDA has approved the first biosimilars for denosumab that reference Amgen’s osteroporisis drug Prolia and the bone cancer drug Xgeva. Developed by Sandoz, both biosimilars are interchangeable with the reference products for all indications.
Wyost (denosumab-bbdz) is approved to prevent skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. It is also approved to treat adults and skeletally mature adolescents with giant cell tumor of bone and hypercalcemia of malignancy refractory to bisphosphonate therapy.
Bone is the third most frequent site for metastatic tumors. Nearly all types of...
Today's Sponsors
Today's Sponsor